Wuhan YZY Biopharma Co (HKSE:02496) EV-to-EBITDA : (As of Jun. 05, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wuhan YZY Biopharma Co's enterprise value is HK$1,327.09 Mil. Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's EV-to-EBITDA at this moment.

The historical rank and industry rank for Wuhan YZY Biopharma Co's EV-to-EBITDA or its related term are showing as below:

HKSE:02496' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.23 Med: 0 Max: 0
Current: -6.67

HKSE:02496's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs HKSE:02496: -6.67

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Wuhan YZY Biopharma Co's stock price is HK$7.45. Wuhan YZY Biopharma Co does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Wuhan YZY Biopharma Co's PE Ratio at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Wuhan YZY Biopharma Co EV-to-EBITDA Historical Data

The historical data trend for Wuhan YZY Biopharma Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co EV-to-EBITDA Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBITDA

-8.08

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Dec23
EV-to-EBITDA	-	-	-8.08

Competitive Comparison of Wuhan YZY Biopharma Co's EV-to-EBITDA

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's EV-to-EBITDA falls into.

Wuhan YZY Biopharma Co EV-to-EBITDA Calculation

Wuhan YZY Biopharma Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	1327.088	/
	=

Wuhan YZY Biopharma Co (HKSE:02496) EV-to-EBITDA Explanation

Wuhan YZY Biopharma Co's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	7.45	/
	=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Wuhan YZY Biopharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com/

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.

Executives

Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie	2201 Interest of corporation controlled by you
Wu Shangzhi	2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines